Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.
Research Interests

Papers共 150 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Updated Efficacy and Safety from the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients with BRAF V600E-Mutant Metastatic NSCLC‒A Brief Report
Gregory J Riely,Myung-Ju Ahn, Jeffrey M Clarke,Ibiayi Dagogo-Jack, Raymond Esper,Enriqueta Felip,Francesco Gelsomino, Jonathan W Goldman, Maen Hussein,Melissa Johnson,Kristen A Marrone,Daniel Morgensztern,Ernest Nadal,Marcelo V Negrao,Michael Offin,Mariano Provencio, Suresh S Ramalingam, Logan Roof, Rachel E Sanborn, Egbert F Smit,Anne Tsao,Tiziana Usari, Ann Alcasid, Keith Wilner, Svitlana Tonkovyd, Xiaosong Zhang, Bruce E Johnson
Journal of thoracic oncology official publication of the International Association for the Study of Lung Cancer (2025)
Cited0Views0WOSBibtex
0
0
Brief Report: Durvalumab Combined with Pemetrexed-Based Chemotherapy in Trial Ineligible Mesothelioma Patients
Ibiayi Dagogo-Jack, Aubrey Lasko,Elizabeth A. Krueger, Kitman Tsang, Revati Rao, Grace Hambelton,Subba R. Digumarthy
JTO Clinical and Research Reportspp.100775, (2024)
Cited0Views0WOSBibtex
0
0
LBA56 Updated Efficacy and Safety from the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients with BRAF V600E-mutant Metastatic NSCLC (Mnsclc)
G.J. Riely,M-J. Ahn, J. Clarke,I. Dagogo-Jack,E. Felip,F. Gelsomino,J.W. Goldman, M. Hussein, M.L. Johnson,D. Morgensztern, E. Nadal,M.D. Offin, M. Provencio Pulla, S.S. Ramalingam, E.F. Smit,A.S. Tsao, A. Alcasid,T. Usari,K. Wilner, B. Johnson
Annals of Oncology (2024): S1246-S1247
Cited0Views0Bibtex
0
0
Load More
Author Statistics

#Papers: 150

#Citation: 6412

H-Index: 35

G-Index: 79

Sociability: 7

Diversity: 3

Activity: 62

  • 合作者
  • 学生
  • 导师
No result temporarily, you can search similar Scholar with the same research interest
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn